Effects of neoadjuvant VEGF-TKI treatment on surgery for renal cell carcinoma: A systematic review and meta-analysis

被引:2
|
作者
Zhu, Meikai [1 ]
Liu, Zhifeng [2 ]
Zhou, Yongheng [1 ]
Jiang, Zhiwen [1 ]
Chen, Shouzhen [1 ]
Wang, Wenfu [1 ]
Shi, Benkang [1 ]
Zhu, Yaofeng [1 ]
机构
[1] Shandong Univ, Qilu Hosp, Dept Urol, 107 Wenhua West Rd, Jinan 250012, Shandong, Peoples R China
[2] Taian City Cent Hosp, Dept Urol, Tai An 271000, Shandong, Peoples R China
关键词
neoadjuvant therapy; targeted therapy; renal cell carcinoma; surgical treatment; nephrectomy; TARGETED MOLECULAR THERAPIES; VENA-CAVA THROMBECTOMY; PARTIAL NEPHRECTOMY; TUMOR THROMBUS; SUNITINIB; SORAFENIB; AXITINIB; CANCER; TRIAL;
D O I
10.3892/ol.2024.14295
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
To evaluate the effects of neoadjuvant vascular endothelial growth factor-tyrosine kinase inhibitor (VEGF-TKI) treatment on surgery in patients with renal cell carcinoma (RCC), sources from Embase, PubMed and the Cochrane Library databases collected from inception to December, 2022 were used for analysis in the present study, according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. Data regarding surgical outcomes were collected. The pooled effect sizes were calculated in terms of the risk ratio (RR)/standard mean difference (SMD) with 95% confidence intervals (CIs) using the random-effects model. Subgroup and sensitivity analyses were used to explore the source of heterogeneity within the data. In total, 9 identified articles involving 829 patients (336 in the neoadjuvant + surgery group; 493 in the surgery group) were included in the present study, according to the criteria. The results demonstrated that there were no significant differences in blood loss (SMD=-0.11; 95% CI, -0.63-0.41; P=0.68), postoperative length of hospital stay or total length of hospital stay (SMD=0.23; 95% CI, -0.55-1.01; P=0.57) or complications (RR=1.16; 95% CI, 0.80-1.67; P=0.44) between the two groups. However, neoadjuvant therapy reduced the operation time (SMD=-0.67; 95% CI, -1.25- -0.09; P=0.02) and resulted in a greater proportion of patients choosing partial nephrectomy (RR=1.84; 95% CI, 1.47-2.31; P<0.00001). In the subgroup analysis, the blood loss was significantly lower in patients with RCC with inferior vena cava tumor thrombus in the neoadjuvant group (SMD=-1.10; 95% CI, -1.82- -0.38; P=0.003). In conclusion, the results of the present study indicated that neoadjuvant VEGF-TKI treatment in patients with RCC shortened operation time, decreased blood loss and did not cause an increase in perioperative complications. In addition, this treatment modality may encourage patients to opt for partial nephrectomy to preserve renal function.
引用
收藏
页数:8
相关论文
共 50 条
  • [21] The efficacy of neoadjuvant chemotherapy as compared to upfront surgery for the management of oral squamous cell carcinoma: a systematic review and meta-analysis
    Kende, P.
    Mathur, Y.
    Tayal, S.
    Patyal, N.
    Landge, J.
    INTERNATIONAL JOURNAL OF ORAL AND MAXILLOFACIAL SURGERY, 2024, 53 (01) : 1 - 10
  • [22] First-line Treatment of Metastatic Renal Cell Carcinoma: A Systematic Review and Network Meta-analysis
    Hahn, Andrew W.
    Klaassen, Zachary
    Agarwal, Neeraj
    Haaland, Benjamin
    Esther, John
    Ye, Xiang Y.
    Wang, Xuechen
    Pal, Sumanta K.
    Wallis, Christopher J. D.
    EUROPEAN UROLOGY ONCOLOGY, 2019, 2 (06): : 708 - 715
  • [23] A Comparison of Microwave Ablation and Cryoablation for the Treatment of Renal Cell Carcinoma: A Systematic Literature Review and Meta-analysis
    McClure, Timothy
    Lansing, Austin
    Ferko, Nicole
    Wright, George
    Ghosh, Sudip K.
    Raza, Sajjad
    Kalsekar, Iftekhar
    Clarke, Kerise
    Talenfeld, Adam
    UROLOGY, 2023, 180 : 1 - 8
  • [24] Neoadjuvant immunotherapy for resectable hepatocellular carcinoma: a systematic review and meta-analysis
    Han, Y. -H.
    Bo, J. -Q.
    Liu, L. -X.
    EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES, 2023, 27 (15) : 7134 - 7147
  • [25] Immunoglobulin as a predictive biomarker for the efficacy of immune checkpoint inhibitor combined with VEGF-TKI in metastatic renal cell carcinoma.
    Cui, Honglei
    Wu, Jie
    Qu, Wang
    Hu, Linjun
    Zhou, Ai-Ping
    Shou, Jian-Zhong
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [26] A systematic review and meta-analysis of adjuvant chemotherapy after neoadjuvant treatment and surgery for rectal cancer
    Petrelli, Fausto
    Coinu, Andrea
    Lonati, Veronica
    Barni, Sandro
    INTERNATIONAL JOURNAL OF COLORECTAL DISEASE, 2015, 30 (04) : 447 - 457
  • [27] A systematic review and meta-analysis of adjuvant chemotherapy after neoadjuvant treatment and surgery for rectal cancer
    Fausto Petrelli
    Andrea Coinu
    Veronica Lonati
    Sandro Barni
    International Journal of Colorectal Disease, 2015, 30 : 447 - 457
  • [28] Neoadjuvant Chemoimmunotherapy for Resectable Head and Neck Squamous Cell Carcinoma: Systematic Review and Meta-analysis
    Cao, Lei-Ming
    Yu, Yi-Fu
    Li, Zi-Zhan
    Wang, Guang-Rui
    Xiao, Yao
    Luo, Han-Yue
    Liu, Bing
    Bu, Lin-Lin
    ANNALS OF SURGICAL ONCOLOGY, 2025,
  • [29] Is neoadjuvant chemotherapy followed by surgery the appropriate treatment for esophagogastric signet ring cell carcinomas? A systematic review and meta-analysis
    Schiefer, Sabine
    Crnovrsanin, Nerma
    Kalkum, Eva
    Vey, Johannes A.
    Nienhueser, Henrik
    Rompen, Ingmar F.
    Haag, Georg M.
    Mueller-Stich, Beat
    Billmann, Franck
    Schmidt, Thomas
    Probst, Pascal
    Klotz, Rosa
    Sisic, Leila
    FRONTIERS IN SURGERY, 2024, 11
  • [30] Re: Genomics of Clear-Cell Renal Cell Carcinoma: A Systematic Review and Meta-Analysis
    Bui, T. O.
    Dao, V. T.
    Nguyen, V. T.
    Feugeas, J. -P.
    Pamoukdjian, F.
    Bousquet, G.
    JOURNAL OF UROLOGY, 2022, 208 (03): : 732 - 733